Last reviewed · How we verify
FK199B
FK199B is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.
FK199B is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for Complement-mediated inflammatory disorders (specific indication under investigation in Phase 3).
At a glance
| Generic name | FK199B |
|---|---|
| Also known as | Zolpidem MR Tablet |
| Sponsor | Astellas Pharma Inc |
| Drug class | C5a receptor antagonist |
| Target | C5a receptor (C5aR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
FK199B blocks the C5a receptor on immune cells, preventing the recruitment and activation of neutrophils and other inflammatory cells downstream of complement cascade activation. This mechanism reduces tissue damage and inflammation in complement-driven diseases. It represents a targeted approach to modulating innate immunity without broad immunosuppression.
Approved indications
- Complement-mediated inflammatory disorders (specific indication under investigation in Phase 3)
Common side effects
Key clinical trials
- Zolpidem Postmarketing Study in Adolescent Patients With Insomnia (PHASE4)
- A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia (PHASE3)
- A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients (PHASE3)
- A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FK199B CI brief — competitive landscape report
- FK199B updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI